Pharmaceutical analysis for a patient with rebamipide-induced Stevens-Johnson syndrome by clinical pharmacists
- VernacularTitle:临床药师对1例瑞巴派特致Stevens-Johnson综合征的药学分析
- Author:
Wenjun GONG
1
;
Jian ZOU
1
;
Han XU
2
;
Yuan BIAN
3
Author Information
1. Dept. of Clinical Pharmacy，Pengzhou Municipal People’s Hospital，Sichuan Pengzhou 611930，China
2. Dept. of Clinical Pharmacy，the Affiliated Zigong Hospital of Southwest Medical University，Sichuan Zigong 643020，China
3. Personalized Drug Therapy Key Laboratory of Sichuan Province，Dept. of Pharmacy of Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital/Affiliated Hospital of University of Electronic Science and Technology，Chengdu 610072，China
- Publication Type:Journal Article
- Keywords:
rebamipide;
Stevens-Johnson syndrome;
adverse
- From:
China Pharmacy
2023;34(10):1262-1265
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for the diagnosis and treatment of Stevens-Johnson syndrome caused by rebamipide， and to explore the predisposing factors of Stevens-Johnson syndrome. METHODS Clinical pharmacists analyzed the treatment process of a patient with gastrointestinal diseases and evaluated the correlation between the drug used and adverse reactions， in order to determine the suspected allergenic drug causing Stevens-Johnson syndrome. The predisposing factors of patients with Stevens-Johnson syndrome were explored. RESULTS & CONCLUSIONS The suspected allergenic drugs that caused the patient to develop Stevens-Johnson syndrome included Ilaprazole enteric-coated tablets， Rebamipide tablets and Kangfuxin liquid. In summary， the suspect drug was identified as Rebamipide tablets according to the causality evaluation method of the National Center for Adverse Drug Reaction Monitoring， Naranjo’s scoring method and the algorithm of drug causality for epidermal necrolysis scoring criteria. Hypoproteinemia， competitive binding of plasma proteins between drugs， advanced age， bacterial and viral infections were the predisposing factors of Stevens-Johnson syndrome. Therefore， before using rebamipide in clinical practice， it is necessary to inquire about the patient’s allergy history in detail. During the use process， it is necessary to strengthen the patient’s medication monitoring and be alert to the occurrence of serious adverse reactions. If any abnormalities are found， the medication should be stopped immediately and symptomatic treatment should be given as soon as possible to ensure the safety and effectiveness of the patient’s medication.
